NASDAQ:OMCL - Omnicell Stock Price, Forecast & News

Omnicell trades on the NASDAQ under the ticker symbol "OMCL."

Omnicell, Inc. (NASDAQ:OMCL) released its quarterly earnings data on Thursday, October, 24th. The company reported $0.76 EPS for the quarter, topping analysts' consensus estimates of $0.71 by $0.05. The firm had revenue of $228.80 million for the quarter, compared to the consensus estimate of $231.86 million. Omnicell had a return on equity of 11.90% and a net margin of 6.28%. The firm's revenue was up 12.0% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.63 earnings per share. View Omnicell's Earnings History.

Omnicell is scheduled to release their next quarterly earnings announcement on Thursday, February 6th 2020. View Earnings Estimates for Omnicell.

Omnicell updated its fourth quarter earnings guidance on Thursday, October, 24th. The company provided earnings per share (EPS) guidance of $0.75-0.80 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.79. The company issued revenue guidance of $240-246 million, compared to the consensus revenue estimate of $243.20 million.

7 equities research analysts have issued 1 year price targets for Omnicell's shares. Their forecasts range from $70.00 to $95.00. On average, they anticipate Omnicell's stock price to reach $85.57 in the next twelve months. This suggests that the stock has a possible downside of 0.4%. View Analyst Price Targets for Omnicell.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Omnicell in the last year. There are currently 3 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Omnicell.

Media coverage about OMCL stock has trended somewhat negative recently, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Omnicell earned a media sentiment score of -1.5 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 1.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the next few days. View News Stories for Omnicell.

Omnicell saw a decline in short interest during the month of December. As of December 13th, there was short interest totalling 2,100,000 shares, a decline of 7.9% from the November 28th total of 2,280,000 shares. Based on an average daily trading volume, of 239,800 shares, the days-to-cover ratio is presently 8.8 days. Approximately 5.1% of the shares of the stock are short sold. View Omnicell's Current Options Chain.

Some companies that are related to Omnicell include Cerner (CERN), HMS (HMSY), Cortexyme (CRTX), Allscripts Healthcare Solutions (MDRX), HealthStream (HSTM), Vocera Communications (VCRA) and Computer Programs & Systems (CPSI).

Based on aggregate information from My MarketBeat watchlists, some companies that other Omnicell investors own include AT&T (T), Micron Technology (MU), Netflix (NFLX), NVIDIA (NVDA), AbbVie (ABBV), Alibaba Group (BABA), Bank of America (BAC), Johnson & Johnson (JNJ), Adobe (ADBE) and Paypal (PYPL).

Omnicell's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Peregrine Capital Management LLC (0.71%), Tributary Capital Management LLC (0.63%), Summit Creek Advisors LLC (0.63%), Scout Investments Inc. (0.43%), Rhenman & Partners Asset Management AB (0.23%) and Calamos Advisors LLC (0.13%). Company insiders that own Omnicell stock include Dan S Johnston, Gary S Petersmeyer, James T Judson, Joanne B Bauer, Jorge R Taborga, Joseph Brian Spears, Nhat H Ngo, Peter J Kuipers, Randall A Lipps, Robin Gene Seim and Scott Peter Seidelmann. View Institutional Ownership Trends for Omnicell.

OMCL stock was sold by a variety of institutional investors in the last quarter, including Bowling Portfolio Management LLC, Tributary Capital Management LLC, Scout Investments Inc., Assenagon Asset Management S.A., Louisiana State Employees Retirement System, State of Alaska Department of Revenue and West Coast Financial LLC. Company insiders that have sold Omnicell company stock in the last year include Dan S Johnston, Gary S Petersmeyer, Joanne B Bauer, Jorge R Taborga, Joseph Brian Spears, Nhat H Ngo, Peter J Kuipers, Randall A Lipps and Scott Peter Seidelmann. View Insider Buying and Selling for Omnicell.

OMCL stock was acquired by a variety of institutional investors in the last quarter, including Summit Creek Advisors LLC, Peregrine Capital Management LLC, DNB Asset Management AS, Calamos Advisors LLC, Rhenman & Partners Asset Management AB, First National Bank of Omaha, SFE Investment Counsel and OLD National Bancorp IN. View Insider Buying and Selling for Omnicell.

Shares of OMCL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of OMCL stock can currently be purchased for approximately $85.93.

Omnicell has a market capitalization of $3.60 billion and generates $787.31 million in revenue each year. The company earns $37.73 million in net income (profit) each year or $1.53 on an earnings per share basis. Omnicell employs 2,480 workers across the globe.View Additional Information About Omnicell.

The official website for Omnicell is http://www.omnicell.com/.

Omnicell's mailing address is 590 EAST MIDDLEFIELD ROAD, MOUNTAIN VIEW CA, 94043. The company can be reached via phone at 650-251-6100 or via email at [email protected]